Long intergenic non-protein coding RNA 609 (LINC00609)

**Long intergenic non-protein coding RNA 609 (LINC00609)** is a member of the long intergenic non-coding RNA (lincRNA) family, which are autonomously transcribed RNA molecules longer than 200 nucleotides that do not overlap annotated coding genes[1][3][5]. Like other lincRNAs, LINC00609 is not known to encode a protein, but may be involved in *fine-tuning gene expression* through various mechanisms such as chromatin remodeling, transcriptional regulation, and possible enhancer-like activity[3][5]. There is currently no evidence that LINC00609 serves as a direct therapeutic target (e.g., receptor, enzyme, transporter); nor is there evidence for direct interaction with drugs, clear disease biomarkers, or distinct safety/therapeutic concerns. It is annotated as a marker in transcriptomic studies of diverse cell types, including in studies analyzing oligodendrocyte subpopulations in the central nervous system, but no direct disease mechanism or biomarker role has been established[4]. **Notes and context:** - LINC00609 is not a protein, receptor, enzyme, transporter, or classical drug target. It is a non-coding RNA gene and not a direct therapeutic target[1][3][5]. - Its primary recognized functions are linked to gene regulatory and chromatin-associated processes as typical for lincRNAs[3][5]. - While some lincRNAs are linked to specific diseases or cellular phenotypes, there is currently no direct evidence establishing LINC00609 as a disease gene or therapeutic marker. - It has been reported as part of specific transcriptomic cell type signatures but lacks further experimental characterization linking it to canonical disease pathways or drug interactions[4].

Other names

LINC00609long intergenic non-coding RNA 609Long intergenic non-protein coding RNA 609